Trial Profile
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Jul 2021 Results (N=29) presented at the 23rd World Congress on Gastrointestinal Cancer
- 02 Dec 2020 Status changed from not yet recruiting to recruiting.
- 25 Jan 2020 Results (n=26) assessing efficacy and safety of nivolumab and ipilimumab in patients with resectable hepatocellular carcinoma, presented at the 2020 Gastrointestinal Cancers Symposium.